Does the presence of interstitial lung disease affect your decision to offer SBRT for early stage NSCLC?  

Specifically in O2-dependent patients? Have any dose/fractionation regimens been shown to reduce the risk of pneumonitis in this population?



Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at National Cancer Institute
Can you please clarify what you meant by ‚Äúsmall‚...
Radiation Oncologist at Stanford University School of Medicine
As opposed to interstitial lung disease (ILD) in g...
Sign in or Register to read more